Data were obtained from the Web of Science (WoS), Scopus, and PubMed databases. The search strategy employed was as follows: (i) WoS: ((TS = (gamma-aminobutyric acid)) OR TS = (4-Aminobutyric acid)) AND TS = (Parkinson’s disease). (ii) Scopus: (([TITLE-ABS-KEY](gamma-aminobutyric acid)) OR ([TITLE-ABS-KEY]((4-Aminobutyric acid))) AND ([TITLE-ABS-KEY](Parkinson’s disease)). (iii) PubMed: ((gamma-aminobutyric acid[Title/Abstract]) OR (4-Aminobutyric acid[Title/Abstract])) AND (Parkinson’s disease[Title/Abstract]). The inclusion criteria were as follows: (i) Publication date from January 1, 2001, to December 31, 2024; (ii) Publication type restricted to articles and reviews; (iii) Language restricted to English. The exclusion criteria were: (i) The EndNote software eliminated duplicate publications by the same author. (ii) Exclusion of publications irrelevant to the research topic. Following the application of these criteria, 630 publications relevant to GABA and PD were identified (Figure 1).

We employed the software tools VOSviewer (1.6.18) and CiteSpace (6.2.R3) to analyze annual publication trends, countries, institutions, journals, authors, and keywords. This approach is consistent with methodologies established in prior literature (Chen et al., 2025). CiteSpace is a specialized tool for visualizing and mapping knowledge domains within scientific literature. It facilitates the identification of emerging research frontiers, evolutionary trends, and the dynamic patterns of disciplinary development (Chen, 2004). VOSviewer is widely recognized for its intuitive visualization of co-occurrence networks. It utilizes color clustering and density views to illustrate the association strength among elements such as keywords and authors, enabling the efficient construction of data networks (van Eck and Waltman, 2010).

A total of 630 publications related to GABA and PD were obtained. Annual publication numbers exhibited an upward fluctuation (Figure 2A). Research on GABA in PD accounted for a relatively small proportion of all published PD research (Figure 2B). The research on GABA in PD accounted for a relatively small proportion of the PD-related studies listed in the WoS (95,413 publications) (Figure 2B).

The world map indicated that GABA-PD publications were concentrated in Asia and North America, with relatively few publications from South America and Africa (Figure 3A). In the country collaboration network, node size corresponds to publication volume, and line thickness indicates collaboration strength (Figure 3B). The United States and China have made significant contributions to GABA-PD research. The United States was the most active country (184 publications), followed by China (128 publications) and Italy (54 publications) (Table 1).

Karolinska Institute was the most active institution (21 publications), followed by the University of Ferrara (16 publications) and Emory University (14 publications). The top 10 institutions represented three continents: North America, Europe, and Asia, encompassing six countries (Table 2).

According to Bradford’s law, we identified 17 core journals relevant to the topic (Figure 4A). Within PD research, studies on GABA have not yet achieved wide interdisciplinary integration; the field remains predominantly centered within neurology. Neuroscience published the most articles (23 publications), followed by Movement Disorders (22 publications) and Neuropharmacology (21 publications) (Figure 4B and Table 3).

Highly productive authors constitute a dominant force in this research field. In the author collaboration network, node size corresponds to publication volume (Figure 5). Dr. Morari, Michele was the most productive author (13 publications), followed by Dr. Jian Liu (12 publications) and Dr. Kjell Fuxe (10 publications) (Table 4). These prolific authors have contributed significantly to the advancement of the field.

High-frequency keywords reflect current research focus and enable researchers to rapidly identify core topics. Besides GABA (540 times) and PD (475 times), high-frequency keywords included animals (186 times), male (179 times), DA (174 times), glutamate (140 times), basal ganglia (131 times), metabolism (127 times), substantia nigra (98 times), subthalamic nucleus (92 times), neurons (92 times), globus pallidus (71 times), deep brain stimulation (46 times) (Figure 6A). Cluster #0 aged, #1: middle-aged, #2: disease model, #7: basal ganglia, #9: oxidative stress reflected the core background and pathophysiology of PD. Cluster #3: patch clamp, #4: acetylcholine, #5: 4-aminobutyric acid receptor, #8: microdialysis, #11: serotonin 1b receptor reflected the detailed research methods and complex neurotransmitter interactions. Cluster #6: levodopa, #10: safinamide, #12: gut microbiota reflected the transition from traditional treatment to cutting-edge exploration in PD (Figure 6B). Keyword burst refers to the sudden and significant increase in a keyword at a specific time. “α-synuclein” (2019–2024, strength = 4.92), “anxiety” (2020–2024, strength = 5.23), and “oxidative stress” (2021–2024, strength = 6.84) have exhibited high burst intensity in recent GABA-PD research (Figure 6C and Table 5).

From 2001 to 2024, a total of 630 publications related to GABA and PD were identified. The annual publication count exhibited an upward trend with fluctuations. The United States and China have allocated substantial funding to neuroscience and Parkinson’s disease research, which has directly facilitated investigations into the GABAergic system. As leading contributors in the field, these nations frequently serve as central hubs in large-scale international collaborative networks, thereby reinforcing their prominent roles. Regarding global cooperation, the successful model of the Parkinson’s Progression Markers Initiative could be leveraged to establish an international “GABA-PD Alliance.” Such an alliance could enable the sharing of patient biospecimen repositories with GABA-related pathological data and support multicenter, longitudinal clinical studies to elucidate dynamic changes in the GABAergic system throughout PD progression. Karolinska Institute was the leading research institution. Neuroscience published the most papers on GABA and PD. Dr. Michele Morari was the most prolific author.

High-frequency keywords directly reflect topics of widespread concern within a field and reveal current research focus. In addition to GABA and PD, high-frequency keywords included animals, male, DA, glutamate, basal ganglia, metabolism, substantia nigra (SN), subthalamic nucleus, neurons, globus pallidus (GP), and deep brain stimulation (DBS). The basal ganglia constitute a complex neural network responsible for motor control, learning, emotion regulation, and other functions. Its core nuclei include the striatum, GP, SN, and STN. These nuclei interact through both direct (promoting movement) and indirect (inhibiting movement) pathways to maintain motor balance (Yelnik, 2002). The core pathology of PD involves the degeneration of dopaminergic neurons in the SN pars compacta and reduced DA levels, leading to an imbalance between the indirect and direct pathways of the basal ganglia. Excessive activity within the indirect pathway, primarily mediated by GABAergic neurons, is an important mechanism underlying the development of motor symptoms in PD (Obeso et al., 2008). Glutamate, as an excitatory neurotransmitter, participates in PD progression (Blandini et al., 1996). In PD, decreased GABAergic inhibition and increased glutamatergic excitation form a vicious cycle, resulting in excessive inhibition of the basal ganglia output nuclei (GPi/SNr) on the thalamus and consequent movement disorders (Windels et al., 2003). DBS is an established clinical treatment for PD, and its mechanism of action may involve modulation of the STN-GPe network (Noor et al., 2024).

Keywords such as α-synuclein oxidative stress and anxiety have shown a high burst intensity in recent GABA and PD research. This trend highlights the most active and highly focused core directions and emerging focus in current PD research. α-Synuclein is the core pathological hallmark of PD; its aggregation propagation and toxicity are central to PD pathogenesis (Yaribash et al., 2025). Oxidative stress results from an imbalance between the production and clearance of reactive oxygen species within cells and is considered a key driver of neuronal death in PD (Jenner, 2003). Anxiety is a common non-motor symptom in PD patients and its pathophysiological mechanisms are closely linked to neurotransmitter dysregulation and neural circuit dysfunction associated with PD (Walsh and Bennett, 2001). Abnormal aggregation and propagation of α-synuclein can directly or indirectly induce oxidative stress which in turn exacerbates α-synuclein aggregation and toxicity forming a vicious cycle. The core pathological process of α-synuclein and oxidative stress extensively damages brain neurons and neural circuits (Surmeier et al., 2017). The basal ganglia-thalamocortical circuit and GABAergic interneurons and projection neurons within the limbic system are particularly vulnerable to this damage. Dysfunction of GABAergic signaling in these circuits is regarded as a key mechanism contributing to neuropsychiatric symptoms such as anxiety in PD (Li et al., 2024). These foci reflect an in-depth exploration of PD’S pathological mechanisms. The attention paid to anxiety as a non-motor symptom indicates that it has become a clinically significant research direction in the field of PD studies. The GABAergic system plays a pivotal role in this context acting as a key link connecting upstream core pathology with downstream key clinical symptoms.

In the evaluation of clinical trials targeting the GABAergic system for PD interventions, studies vary in efficacy, methodology, and clinical translational potential. A clinical trial of nabilone (n = 7) showed that it significantly alleviated levodopa-induced dyskinesia. The mechanism may involve inhibition of GABA reuptake in the GP and enhancement of inhibitory transmission; however, this trial had a small sample size, did not assess core motor symptoms, and lacked long-term safety data (Sieradzan et al., 2001). A study on the GABA_A receptor antagonist flumazenil (n = 16) reported improved motor flexibility, although without significant improvement in UPDRS-III scores. Limitations included the short duration of the single-dose effect, lack of long-term safety data, and the common adverse drug reaction of dizziness (Ondo and Silay, 2006). The Zonisamide study (n = 389) demonstrated that 50 mg/day significantly reduced “off” time without increasing the risk of dyskinesia or hallucinations. However, limitations remain: Zonisamide’s multi-target mechanism (MAO-B inhibition, calcium channel regulation) makes it difficult to attribute effects solely to a single GABAergic pathway, and the inclusion of patients already receiving combined treatments such as dopamine agonists may have weakened the observed effect (Murata et al., 2015). A 4-month randomized controlled trial of the NKCC1 inhibitor bumetanide (n = 44) showed that improvement in UPDRS-III scores during the OFF period did not differ significantly between the bumetanide and placebo groups. Furthermore, tolerance was poor, possibly due to insufficient brain penetration of the drug and systemic side effects (Damier et al., 2024). A randomized, double-blind trial of probiotic-M8 combined with conventional drugs for PD treatment (n = 82) reported significant synergistic benefits in improving non-motor symptoms and some motor functions (UPDRS-III score), with good safety. However, limitations include a small sample size, high dropout rate, inadequate analysis of the primary motor endpoint, and methodological constraints resulting in a relatively low level of evidence (Sun et al., 2022). A clinical trial investigating DBS for PD provided direct neurochemical evidence for the role of the GP in human memory processing. The findings revealed the complex and specific regulatory patterns of basal ganglia circuits across different cognitive functions. In the enrolled PD patients, changes in GABA concentration within the GP were closely associated with the type of memory task performed: GABA levels increased during implicit memory tasks but decreased during explicit memory tasks (Buchanan et al., 2015). However, this study had several limitations, including a small sample size (n = 2) and the constrained temporal resolution of microdialysis technology. In a study conducted on PD patients undergoing STN-DBS treatment, brain chemical measurements revealed a significant decrease in GABA concentration in the thalamus (Stefani et al., 2011). The decrease in GABA concentration reduces the inhibitory effect on the thalamus, and is considered a key event for restoring motor function and achieving clinical efficacy. Overall, current clinical evidence for GABA-targeted therapy is generally of low quality (small sample sizes, short study durations). Strategies directly targeting GABA receptors or transporters have demonstrated limited efficacy and are associated with tolerance issues. In contrast, approaches indirectly modulating the GABAergic pathway (such as probiotics regulating neurotransmitter metabolism via the microbiota-gut-brain axis) show potential for improving non-motor symptoms, but alleviation of core motor deficits still requires optimization. Future research should integrate large-sample RCTs, targeted drug delivery technologies, and multi-omics mechanistic studies to clarify the precise therapeutic role of GABAergic modulation in PD.

GABAergic dysfunction contributes to motor symptoms in PD primarily through an imbalance in the basal ganglia’s direct/indirect pathways, leading to excessive inhibition of GPi/SNr output (DeLong and Wichmann, 2007). The successful application of GPi-targeted DBS is the most direct therapeutic manifestation of this mechanism (Wichmann and DeLong, 2016). The role of GABAergic interneurons within cortical-basal ganglia-thalamus circuit microcircuits, particularly in the generation of pathological oscillations, is under active investigation. Beyond the main output nuclei, numerous GABAergic interneurons are present within basal ganglia circuits (such as striatum, GPe, and STN) as well as in related cortical and thalamic regions. These interneurons play a crucial role in fine-tuning information flow and synchronizing neuronal activities, such as the generation of β oscillations in local microcircuits (Devergnas et al., 2014). In PD, DA deficiency may disrupt the normal function of these interneurons, leading to local network excitation-inhibition imbalance and pathological oscillations, which are closely associated with bradykinesia and rigidity (Gittis et al., 2011). The specific mechanisms of the GABA system in non-motor symptoms of PD (such as depression, anxiety, cognitive impairment, sleep disorders, and comorbidities) remain insufficiently studied. GABA, as the primary inhibitory neurotransmitter in the central nervous system, is widely distributed in brain regions involved in emotion, cognition, and sleep regulation (Luscher et al., 2011; Winsky-Sommerer, 2009). GABAergic dysfunction (such as loss of GABAergic neurons, altered receptor expression, and abnormal signal transduction) may significantly contribute to these non-motor symptoms. An in-depth exploration of how GABAergic changes in the cortex, limbic system, and brainstem contribute to specific non-motor symptoms is crucial for developing novel therapies targeting these aspects.

In GABA and PD research, challenges and opportunities coexist. GABAergic neurons in the basal ganglia are distributed across multiple nuclei, and their complex interactions complicate the precise localization of functional abnormalities. DA depletion leads to overactivity of the indirect pathway, which may exacerbate motor inhibition via GABAergic neurons; however, the specific mechanisms are not fully understood. Furthermore, animal models may not fully recapitulate changes in the human GABA system. Poor blood–brain barrier penetration, receptor tolerance, and long-term side effects limit the clinical application of GABAergic drugs. Future validation of drug safety and efficacy requires large-scale, multi-center clinical trials. Despite the complexity of the GABA system in PD posing research challenges, emerging technologies offer broad opportunities for precision therapy development. Gene-editing technologies or viral vectors could modulate GABAergic transmission and potentially repair aberrant circuits. Combining imaging (such as PET/fMRI) or molecular markers to identify PD patient subgroups could facilitate personalized treatment.

In this study, only English-language publications were included during the literature search and screening process. Although this approach is common in bibliometric research to ensure data source consistency and reproducibility, it inevitably introduces a certain degree of language bias. The excluded non-English literature accounted for 8.21% of the retrieved records. Consequently, the findings and analyses presented herein primarily reflect the research landscape of GABA in PD from the perspective of international English-language journals and may not fully represent the global situation in this field. Future studies could provide a more globally representative analysis by incorporating literature from multilingual databases.